Atherton M - Search Results

1

Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats.

LeBlanc AK, Atherton M, Bentley RT, Boudreau CE, Burton JH, Curran KM, Dow S, Giuffrida MA, Kellihan HB, Mason NJ, Oblak M, Selmic LE, Selting KA, Singh A, Tjostheim S, Vail DM, Weishaar KM, Berger EP, Rossmeisl JH, Mazcko C. LeBlanc AK, et al. Among authors: atherton m. Vet Comp Oncol. 2021 Jun;19(2):311-352. doi: 10.1111/vco.12677. Epub 2021 Feb 18. Vet Comp Oncol. 2021. PMID: 33427378 Free PMC article.

2

Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma.

Panjwani MK, Atherton MJ, MaloneyHuss MA, Haran KP, Xiong A, Gupta M, Kulikovsaya I, Lacey SF, Mason NJ. Panjwani MK, et al. Among authors: atherton mj. Oncoimmunology. 2019 Oct 23;9(1):1676615. doi: 10.1080/2162402X.2019.1676615. eCollection 2020. Oncoimmunology. 2019. PMID: 32002286 Free PMC article.

3

Sarcomas-A barren immunological wasteland or field of opportunity for immunotherapy?

Atherton MJ, Lenz JA, Mason NJ. Atherton MJ, et al. Vet Comp Oncol. 2020 Dec;18(4):447-470. doi: 10.1111/vco.12595. Epub 2020 Apr 27. Vet Comp Oncol. 2020. PMID: 32246517 Review.

4

Response-based modification of CHOP chemotherapy for canine B-cell lymphoma.

Benjamin SE, Sorenmo KU, Krick EL, Salah P, Walsh KA, Weinstein NM, Keuler NS, Avery AC, Atherton MJ, Lenz JA. Benjamin SE, et al. Among authors: atherton mj. Vet Comp Oncol. 2021 Sep;19(3):541-550. doi: 10.1111/vco.12693. Epub 2021 Mar 26. Vet Comp Oncol. 2021. PMID: 33729654

5

Genetic re-direction of canine primary T cells for clinical trial use in pet dogs with spontaneous cancer.

Rotolo A, Atherton MJ, Kasper BT, Haran KP, Mason NJ. Rotolo A, et al. STAR Protoc. 2021 Oct 22;2(4):100905. doi: 10.1016/j.xpro.2021.100905. eCollection 2021 Dec 17. STAR Protoc. 2021. PMID: 34746864 Free PMC article.

6

Bite-size introduction to canine hematologic malignancies.

Atherton MJ, Mason NJ. Atherton MJ, et al. Blood Adv. 2022 Jul 12;6(13):4073-4084. doi: 10.1182/bloodadvances.2021005045. Blood Adv. 2022. PMID: 35316831 Free PMC article. Review.

7

Evaluation of the anti-tumour activity of Coriolus versicolor polysaccharopeptide (I'm-Yunity) alone or in combination with doxorubicin for canine splenic hemangiosarcoma.

Gedney A, Salah P, Mahoney JA, Krick E, Martins R, Scavello H, Lenz JA, Atherton MJ. Gedney A, et al. Vet Comp Oncol. 2022 Sep;20(3):688-696. doi: 10.1111/vco.12823. Epub 2022 Apr 25. Vet Comp Oncol. 2022. PMID: 35442554

8

Case Report: Clinical and Serological Hallmarks of Cytokine Release Syndrome in a Canine B Cell Lymphoma Patient Treated With Autologous CAR-T Cells.

Atherton MJ, Rotolo A, Haran KP, Mason NJ. Atherton MJ, et al. Front Vet Sci. 2022 Jul 11;9:824982. doi: 10.3389/fvets.2022.824982. eCollection 2022. Front Vet Sci. 2022. PMID: 35898541 Free PMC article.

9

Evaluation of mechlorethamine, vinblastine, procarbazine, and prednisone for the treatment of resistant multicentric canine lymphoma.

Zimmerman K, Walsh KA, Ferrari JT, Keuler NS, Atherton MJ, Lenz JA. Zimmerman K, et al. Vet Comp Oncol. 2023 Sep;21(3):503-508. doi: 10.1111/vco.12913. Epub 2023 May 24. Vet Comp Oncol. 2023. PMID: 37222086

10

Changes in the serum proteome of canine lymphoma identified by electrophoresis and mass spectrometry.

Atherton MJ, Braceland M, Fontaine S, Waterston MM, Burchmore RJ, Eadie S, Eckersall PD, Morris JS. Atherton MJ, et al. Vet J. 2013 Jun;196(3):320-4. doi: 10.1016/j.tvjl.2012.12.010. Epub 2013 Jan 29. Vet J. 2013. PMID: 23369383

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

129 results

Search Page

Filters